Literature DB >> 4302980

Survival rates in peripheral bronchogenic carcinomas up to four centimeters in diameter presenting as solitary pulmonary nodules.

R J Jackman, C A Good, O T Clagett, L B Woolner.   

Abstract

Entities:  

Mesh:

Year:  1969        PMID: 4302980

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


× No keyword cloud information.
  10 in total

1.  Advantages of continuous positive-pressure breathing in surgical patients.

Authors:  W P Longmire; P Henney
Journal:  Calif Med       Date:  1970-04

2.  [Results of surgical therapy of bronchial cancer].

Authors:  H B Wulff
Journal:  Langenbecks Arch Chir       Date:  1969

3.  A comparison of pathological methods of measuring lung cancer volume.

Authors:  S Binks; C A Clelland; C Layton
Journal:  J Clin Pathol       Date:  1996-08       Impact factor: 3.411

Review 4.  Pre-operative mediastinal evaluation in primary bronchial carcinoma--a review of staging investigations.

Authors:  J A Elliott
Journal:  Postgrad Med J       Date:  1984-02       Impact factor: 2.401

5.  Respiratory cytodiagnosis: study in observer variation and its relation to quality of material.

Authors:  D M Evans; G Shelley
Journal:  Thorax       Date:  1982-04       Impact factor: 9.139

6.  Screening for lung cancer.

Authors:  I W Grant
Journal:  Br Med J (Clin Res Ed)       Date:  1982-04-24

7.  Radiologic errors in patients with lung cancer.

Authors:  J V Forrest; P J Friedman
Journal:  West J Med       Date:  1981-06

8.  Cancer of the lung in women.

Authors:  H R Harley
Journal:  Thorax       Date:  1976-06       Impact factor: 9.139

9.  A comparison of patient survival and tumour growth kinetics in human bronchogenic carcinoma.

Authors:  K M Kerr; D Lamb
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

10.  Survival rates of lung cancer according to histological type.

Authors:  O Campobasso; B Invernizzi; M Musso; F Berrino
Journal:  Br J Cancer       Date:  1974-03       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.